Oxford, United Kingdom

Scancell is a clinical-stage immuno-oncology specialist that is developing two innovative and flexible antibody (AvidiMab and GlyMab) and two therapeutic vaccine platforms (Moditope and ImmunoBody) with the potential to treat various cancers.

Investment Perspective

Scancell is a clinical stage immunology specialist. It has two promising oncology vaccine platforms, Moditope and ImmunoBody, and two antibody technologies, GlyMab (anti-glycans) and AvidiMab, with the potential to treat many solid cancers, either as monotherapy or in combination. Modi-1, the first Moditope programme, is progressing in a Phase I/II trial targeting hard-to-treat tumours with results due through 2023. The lead ImmunoBody programme, currently SCIB1, is in a Phase II study in metastatic melanoma. The broad acting GlyMab antibodies are generating exciting preclinical data, which led to a partnering deal with Genmab. Further such deals are expected. AvidiMab technology will be increasingly employed to enhance avidity and potency. Our rNPV valuation is £300.1m, equivalent to 36.7p per share.

Market information

SymbolPrimary exchanges


Modi-1 successful in first part of Phase I/II trial
Update | 21 Feb 2023
A leader in antibody and vaccine oncology platforms
Outlook | 15 Feb 2023
FY22 results highlight clinical and corporate progress
Lighthouse | 28 Oct 2022

Recent News

ModiFY Phase 1/2 poster at AACR 2023
18 Apr 2023
Encouraging early efficacy data from ModiFY trial
21 Feb 2023
Positive response in COVIDITY trial
13 Feb 2023
Dr Jean-Michel Cosséry appointed Chairman
01 Feb 2023